ArticleInternational journal of molecular sciences2026
Insights on Stereoselective Residue and Degradation of Spirotetramat Enantiomers on
Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
This study established an HPLC-MS/MS method to quantify the enantiomers of spirotetramat in tubifex. To assess the accuracy and precision of the approach, recovery tests were conducted for insecticide. For all enantiomers, the limits of detection were 0.003 mg/kg. The quantization limits were 0.01 mg/kg. Spirotetramat enantiomers recovery rates in tubifex were found to be between 81 and 114%, with relative standard deviations being less than 7%. The half-lives of spirotetramat enantiomers in tubifex were 3.81-10.58 d, respectively. The 22.4% spirotetramat suspension was sprayed on tubifex three times at a low dosage (high dosage advised). After 14 days after harvesting, the terminal residues of spirotetramat enantiomers in the tubifex were less than 0.03 mg/kg. The findings offer a quantitative foundation for setting China's maximum residue limits as well as a recommendation for the safe and responsible usage of spirotetramat enantiomers in tubifex.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.